Next-generation Sequencing Market

Market leaders like Illumina and Roche are using bundled contracts that include reagents, software, and maintenance, turning instrument sales into long-term revenue streams. Thermo Fisher is expanding its reach through complete sequencing solutions using the Ion Torrent Genexus Dx platform. Companies are also forming partnerships, such as Illumina's collaboration with NVIDIA, to offer GPU-accelerated cloud analysis. By 2029, compact sequencers from Oxford Nanopore and Genapsys are expected to expand real-time and remote lab applications.

Latin America, Southeast Asia, and Africa are emerging as high-return markets. In Mexico, the OriGen project is sequencing over 10,000 genomes, making it attractive for local NGS investments. In March 2025, Illumina renewed its partnership with Africa CDC to equip national labs with NGS tools. In Southeast Asia, Gene Solutions partnered with Element Biosciences in April 2025 to bring cost-effective NIPT and oncology assays to Singapore and Vietnam.

FDA fast-track programs have helped companies reduce approval times and generate revenue earlier. In October 2024, Thermo Fisher received FDA approval for the Oncomine Dx Target Test, quickly unlocking cartridge orders and contracts. Illumina’s TruSight Oncology panel was approved in August 2024 and also secured early Medicare coverage, helping the company capture initial sales sooner than expected.

Recent investments are focusing on software, consumables, and hardware innovation. In May 2025, SeqOne Genomics raised USD 23.2 million to expand its AI-driven platform. In January 2025, Senseera secured USD 7.1 million for its liquid biopsy technology. In July 2024, Element Biosciences raised USD 277 million to support its high-throughput AVITI sequencer. These investments indicate a shift toward software development, non-invasive diagnostics, and next-generation instruments.

The market still lacks standardized, cloud-based bioinformatics tools, which could generate strong subscription-based revenue. Fully automated, microfluidic sample-to-answer platforms are another gap that could drive premium consumables and service contracts. Long-read systems that lower sequencing costs are also in demand. Companies like Ultima Genomics and Standard Bio are working to address these areas.

In the Asia Pacific region, companies are forming local partnerships to leverage regulatory and bioinformatics expertise. For instance, in March 2023, Qiagen collaborated with SOPHiA Genetics to combine reagents with analytics in India and Southeast Asia. Illumina introduced the NovaSeqX platform in Thailand in October 2022, reducing per-sample costs and encouraging adoption in cost-sensitive markets.

Regulatory actions and localization efforts are changing how companies manage their supply chains. In March 2025, China banned the import of Illumina sequencers, forcing the company to reduce costs by 100 million dollars and revise its earnings guidance. At the same time, companies like Thermo Fisher have localized production, with its May 2023 facility in Singapore reducing logistics costs and improving margins on consumables.

Sample-to-answer platforms are speeding up adoption by simplifying workflows. Thermo Fisher’s Genexus System completes sequencing and analysis in under 24 hours, helping smaller labs implement NGS. In May 2024, Illumina launched an AI-driven variant calling tool that reduced analysis time to two hours. BGI’s new hub in Singapore now serves over 5,000 institutes with scalable cloud computing resources.

Several national programs are creating demand for NGS technologies. In India, the Genome India Project launched in January 2020 is sequencing 10,000 genomes and building lab infrastructure. China’s 2023 Clinical Sequencing Pilot Program allows early commercialization of various assays. The European Union’s GenAI4EU program, launched in May 2024 under Horizon Europe, is investing 818 million dollars in AI-driven bioinformatics through 2027.

In Asia Pacific, companies are adapting to local needs by developing region-specific products. GeneLife, a Japanese company, partnered with Illumina to create direct-to-consumer kits and a wellness app focused on Asian genetic variants. In October 2022, Pacific Biosciences introduced the Revio and Onso platforms across the region, giving labs a range of affordable and scalable options tailored to varying budgets and throughput demands.